abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 37,925 shares, a decline of 37.6% from the January 15th total of 60,767 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 113,249 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 113,249 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the company’s shares are short sold.

abrdn Life Sciences Investors Trading Up 1.0%

NYSE HQL traded up $0.17 during trading hours on Friday, reaching $16.96. The company had a trading volume of 149,342 shares, compared to its average volume of 117,730. The stock has a 50-day moving average of $16.95 and a 200 day moving average of $15.92. abrdn Life Sciences Investors has a 1-year low of $10.55 and a 1-year high of $17.80.

abrdn Life Sciences Investors Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, February 20th will be given a dividend of $0.56 per share. This represents a $2.24 dividend on an annualized basis and a dividend yield of 13.2%. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50.

Institutional Trading of abrdn Life Sciences Investors

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. WNY Asset Management LLC boosted its position in shares of abrdn Life Sciences Investors by 3.4% during the 2nd quarter. WNY Asset Management LLC now owns 24,955 shares of the company’s stock worth $320,000 after acquiring an additional 821 shares in the last quarter. Kingsview Wealth Management LLC boosted its holdings in abrdn Life Sciences Investors by 2.8% in the second quarter. Kingsview Wealth Management LLC now owns 36,743 shares of the company’s stock valued at $471,000 after purchasing an additional 1,000 shares in the last quarter. Flagship Harbor Advisors LLC increased its stake in abrdn Life Sciences Investors by 0.3% in the second quarter. Flagship Harbor Advisors LLC now owns 341,959 shares of the company’s stock valued at $4,380,000 after purchasing an additional 1,082 shares during the last quarter. Samalin Investment Counsel LLC raised its holdings in abrdn Life Sciences Investors by 6.7% during the second quarter. Samalin Investment Counsel LLC now owns 21,782 shares of the company’s stock worth $279,000 after purchasing an additional 1,366 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its position in shares of abrdn Life Sciences Investors by 0.9% during the 2nd quarter. Advisors Asset Management Inc. now owns 160,173 shares of the company’s stock worth $2,052,000 after buying an additional 1,487 shares during the last quarter. 32.21% of the stock is currently owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.